KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Return on Sales (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Return on Sales data on record, last reported at 0.22% in Q4 2025.

  • For Q4 2025, Return on Sales rose 8762.0% year-over-year to 0.22%; the TTM value through Dec 2025 reached 0.31%, down 33.0%, while the annual FY2025 figure was 0.31%, 0.0% changed from the prior year.
  • Return on Sales reached 0.22% in Q4 2025 per REGN's latest filing, down from 0.39% in the prior quarter.
  • Across five years, Return on Sales topped out at 430.4% in Q2 2021 and bottomed at 96.78% in Q2 2024.
  • Average Return on Sales over 5 years is 8.25%, with a median of 0.27% recorded in 2025.
  • Peak YoY movement for Return on Sales: soared 42994bps in 2021, then crashed -41336bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.21% in 2021, then crashed by -7151bps to 15.08% in 2022, then plummeted by -320bps to 63.37% in 2023, then plummeted by -38bps to 87.4% in 2024, then soared by 100bps to 0.22% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.22% in Q4 2025, 0.39% in Q3 2025, and 0.38% in Q2 2025.